NASDAQ: OCULOcular Therapeutix Inc Stock Ownership - Who owns Ocular Therapeutix?
Insider buying vs selling
Have Ocular Therapeutix Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Todd Anderman | CLO | 2026-10-08 | 11,984 | $7.29 | $87.36kSell |
| Peter Kaiser | CXO | 2026-10-02 | 9,990 | $7.05 | $70.43kSell |
| Jeffrey S. Heier | CSci | 2026-10-02 | 10,869 | $7.05 | $76.63kSell |
| Donald Notman | COO | 2026-08-31 | 1,099 | $10.24 | $11.25kSell |
| Jeffrey S. Heier | CSci | 2026-08-24 | 3,296 | $10.78 | $35.53kSell |
| Sanjay Nayak | CStrat | 2026-08-24 | 1,897 | $10.78 | $20.45kSell |
| Pravin Dugel | CEO;Chair;Pres | 2026-08-24 | 21,649 | $10.77 | $233.16kSell |
| Peter Kaiser | CXO | 2026-08-24 | 3,035 | $10.77 | $32.69kSell |
| Nadia Waheed | Chief Medical Officer | 2026-06-03 | 14,828 | $8.27 | $122.63kSell |
| Jeffrey S. Heier | Chief Scientific Officer | 2026-05-26 | 3,018 | $8.20 | $24.75kSell |
OCUL insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when OCUL insiders and whales buy or sell their stock.
OCUL Shareholders
What type of owners hold Ocular Therapeutix Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Opaleye Management Inc | 4.65% | 10,213,500 | $68.74M | Insider |
| Summer Road LLC | 3.91% | 8,591,401 | $57.82M | Insider |
| Svlsf IV LLC | 2.21% | 4,859,298 | $32.70M | Insider |
| Pravin Dugel | 1.83% | 4,015,235 | $27.02M | Insider |
| Versant Venture Capital III LP | 1.01% | 2,215,384 | $14.91M | Insider |
| Chv II LP | 0.96% | 2,100,138 | $14.13M | Insider |
| Amarpreet Sawhney | 0.57% | 1,245,424 | $8.38M | Insider |
| Antony C. Mattessich | 0.27% | 595,201 | $4.01M | Insider |
| Donald Notman | 0.17% | 366,529 | $2.47M | Insider |
| Sanjay Nayak | 0.15% | 326,898 | $2.20M | Insider |
OCUL vs Biotech Stocks
Ocular Therapeutix Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.